PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • NSCLC - Market size and forecast 2018-2023 • SCLC - Market size and forecast 2018-2023 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bristol-Myers Squibb Company • F. Hoffmann-La Roche Ltd • Merck & Co., Inc. • Novartis AG • Pfizer Inc. PART 15: APPENDIX • Research methodology • List of abbreviations PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global lung cancer therapeutics market pipeline: Overview Exhibit 18: Global lung cancer therapeutics market pipeline: Overview Exhibit 19: Type - Market share 2018-2023 (%) Exhibit 20: Comparison by type Exhibit 21: NSCLC - Market size and forecast 2018-2023 ($ millions) Exhibit 22: NSCLC - Year-over-year growth 2019-2023 (%) Exhibit 23: SCLC - Market size and forecast 2018-2023 ($ millions) Exhibit 24: SCLC - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by type Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Top 3 countries in North America Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in Europe Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Asia Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in ROW Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: New cases and mortality rates of lung cancer in 2008 Exhibit 44: Impact of drivers and challenges Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Bristol-Myers Squibb Company - Vendor overview Exhibit 51: Bristol-Myers Squibb Company - Business segments Exhibit 52: Bristol-Myers Squibb Company - Organizational developments Exhibit 53: Bristol-Myers Squibb Company - Geographic focus Exhibit 54: Bristol-Myers Squibb Company - Key offerings Exhibit 55: Bristol-Myers Squibb Company - Key customers Exhibit 56: F. Hoffmann-La Roche Ltd - Vendor overview Exhibit 57: F. Hoffmann-La Roche Ltd - Business segments Exhibit 58: F. Hoffmann-La Roche Ltd - Organizational developments Exhibit 59: F. Hoffmann-La Roche Ltd - Geographic focus Exhibit 60: F. Hoffmann-La Roche Ltd - Segment focus Exhibit 61: F. Hoffmann-La Roche Ltd - Key offerings Exhibit 62: F. Hoffmann-La Roche Ltd - Key customers Exhibit 63: Merck & Co., Inc. - Vendor overview Exhibit 64: Merck & Co., Inc. - Business segments Exhibit 65: Merck & Co., Inc. - Organizational developments Exhibit 66: Merck & Co., Inc. - Geographic focus Exhibit 67: Merck & Co., Inc. - Segment focus Exhibit 68: Merck & Co., Inc. - Key offerings Exhibit 69: Merck & Co., Inc. - Key customers Exhibit 70: Novartis AG - Vendor overview Exhibit 71: Novartis AG - Business segments Exhibit 72: Novartis AG - Organizational developments Exhibit 73: Novartis AG - Geographic focus Exhibit 74: Novartis AG - Segment focus Exhibit 75: Novartis AG - Key offerings Exhibit 76: Novartis AG - Key customers Exhibit 77: Pfizer Inc. - Vendor overview Exhibit 78: Pfizer Inc. - Business segments Exhibit 79: Pfizer Inc. - Organizational developments Exhibit 80: Pfizer Inc. - Geographic focus Exhibit 81: Pfizer Inc. - Segment focus Exhibit 82: Pfizer Inc. - Key offerings Exhibit 83: Pfizer Inc. - Key customers Exhibit 84: Validation techniques employed for market sizing

Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd Merck & Co., Inc. Novartis AG Pfizer Inc.